Ardelyx (FRA:41X) LT-Debt-to-Total-Asset : 0.35 (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Ardelyx LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Ardelyx's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.35.

Ardelyx's long-term debt to total assets ratio increased from Dec. 2023 (0.17) to Dec. 2024 (0.35). It may suggest that Ardelyx is progressively becoming more dependent on debt to grow their business.

Ardelyx LT-Debt-to-Total-Asset Historical Data

The historical data trend for Ardelyx's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ardelyx LT-Debt-to-Total-Asset Chart

Ardelyx Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.23

0.07

0.03

0.17

0.35

Ardelyx Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.17	0.29	0.30	0.28	0.35

Ardelyx LT-Debt-to-Total-Asset Calculation

Ardelyx's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	145.042	/	416.145
	=	0.35

Ardelyx's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	145.042	/	416.145
	=	0.35

Ardelyx (FRA:41X) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Ardelyx LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Ardelyx's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Ardelyx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ardelyx Inc (FRA:41X) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

ARDX:USA 41X:Germany

Address

400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451

Website

https://www.ardelyx.com

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Ardelyx Headlines

No Headlines